{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:00:29Z","timestamp":1789426829915,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recent evidence suggests that aromatase may be involved in the pathogenesis of malignant mesothelioma. Here, we evaluated the effect of exemestane, an inhibitor of aromatase, in the treatment of mesothelioma using <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> preclinical models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We show a significant reduction of cell proliferation, survival, migration and block of cells in S phase of cell cycle in mesothelioma cells upon exemestane treatment. Moreover, we find that CD44, which is involved in mesothelioma cells migration, was modulated by exemestane via cAMP and pCREB. Most importantly, in mice mesothelioma xenograft exemestane causes a significant decrease in tumor size and the association pemetrexed\/exemestane is more effective than pemetrexed\/cisplatin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The preclinical mesothelioma model suggests that exemestane might be beneficial in mesothelioma treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/1476-4598-13-69","type":"journal-article","created":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T18:02:37Z","timestamp":1395424957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["RETRACTED ARTICLE: Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease"],"prefix":"10.1186","volume":"13","author":[{"given":"Barbara","family":"Nuvoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Germoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Morosetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaela","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iole","family":"Cordone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Galati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,21]]},"reference":[{"key":"1270_CR1","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1378\/chest.106.5.1611","volume":"106","author":"LA Robinson","year":"1994","unstructured":"Robinson LA, Reilly RB: Localized pleural mesothelioma. The clinical spectrum. Chest. 1994, 106: 1611-1615. 10.1378\/chest.106.5.1611","journal-title":"Chest"},{"key":"1270_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1165\/ajrcmb.17.6.f141","volume":"17","author":"VC Broaddus","year":"1997","unstructured":"Broaddus VC: Asbestos, the mesothelial cell and malignancy: a matter of life or death. Am J Respir Cell Mol Biol. 1997, 17: 657-659. 10.1165\/ajrcmb.17.6.f141","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1270_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2486\/indhealth.39.65","volume":"39","author":"K Morinaga","year":"2001","unstructured":"Morinaga K, Kishimoto T, Sakatani M, Akira M, Yokoyama K, Sera Y: Asbestos-related lung cancer and mesothelioma in Japan. Ind Health. 2001, 39: 65-74. 10.2486\/indhealth.39.65","journal-title":"Ind Health"},{"key":"1270_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1164\/ajrccm.153.2.8564122","volume":"153","author":"A Dufresne","year":"1996","unstructured":"Dufresne A, B\u00e9gin R, Churg A, Mass\u00e9 S: Mineral fiber content of lungs in patients with mesothelioma seeking compensation in Quebec. Am J Respir Crit Care Med. 1996, 153: 711-718. 10.1164\/ajrccm.153.2.8564122","journal-title":"Am J Respir Crit Care Med"},{"key":"1270_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.thorsurg.2004.06.003","volume":"14","author":"HI Pass","year":"2004","unstructured":"Pass HI, Bocchetta M, Carbone M: Evidence of an important role for SV40 in mesothelioma. Thorac Surg Clin. 2004, 14: 489-495. 10.1016\/j.thorsurg.2004.06.003","journal-title":"Thorac Surg Clin"},{"key":"1270_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2486\/indhealth.45.379","volume":"45","author":"C Bianchi","year":"2007","unstructured":"Bianchi C, Bianchi T: Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health. 2007, 45: 379-387. 10.2486\/indhealth.45.379","journal-title":"Ind Health"},{"key":"1270_CR7","first-page":"491","volume":"1","author":"BM Robinson","year":"2012","unstructured":"Robinson BM: Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012, 1: 491-496.","journal-title":"Ann Cardiothorac Surg"},{"key":"1270_CR8","doi-asserted-by":"publisher","first-page":"61S","DOI":"10.1378\/chest.113.1_Supplement.61S","volume":"113","author":"DJ Sugarbaker","year":"1998","unstructured":"Sugarbaker DJ, Norberto JJ: Multimodality management of malignant pleural mesothelioma. Chest. 1998, 113: 61S-65S. 10.1378\/chest.113.1_Supplement.61S","journal-title":"Chest"},{"key":"1270_CR9","first-page":"19","volume":"17","author":"A Abakay","year":"2013","unstructured":"Abakay A, Abakay O, Tanrikulu AC, Sezgi C, Sen H, Kaya H, Kucukoner M, Kaplan MA, Celik Y, Senyigit A: Effects of treatment regimens on survival in patients with malignant pleural mesothelioma. Eur Rev Med Pharmacol Sci. 2013, 17: 19-24.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1270_CR10","first-page":"508","volume":"1","author":"AK Nowak","year":"2012","unstructured":"Nowak AK: Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. Ann Cardiothorac Surg. 2012, 1: 508-515.","journal-title":"Ann Cardiothorac Surg"},{"key":"1270_CR11","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"15","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003, 15: 2636-2644.","journal-title":"J Clin Oncol"},{"key":"1270_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.molonc.2012.11.004","volume":"7","author":"PF Cartron","year":"2013","unstructured":"Cartron PF, Blanquart C, Hervouet E, Gregoire M, Vallette FM: HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression. Mol Onco. 2013, 7: 452-463. 10.1016\/j.molonc.2012.11.004.","journal-title":"Mol Onco"},{"key":"1270_CR13","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1158\/1078-0432.CCR-12-0599","volume":"18","author":"Y Shi","year":"2012","unstructured":"Shi Y, Moura U, Opitz I, Soltermann A, Rehrauer H, Thies S, Weder W, Stahel RA, Felley-Bosco E: Role of hedgehog signaling in malignant pleural mesothelioma. Clin Cancer Res. 2012, 18: 4646-4656. 10.1158\/1078-0432.CCR-12-0599","journal-title":"Clin Cancer Res"},{"key":"1270_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1756-9966-32-7","volume":"32","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, He J, Zhang F, Li H, Yue D, Wang C, Jablons DM, He B, Lui N: SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma. J Exp Clin Cancer Res. 2013, 32: 7- 10.1186\/1756-9966-32-7","journal-title":"J Exp Clin Cancer Res"},{"key":"1270_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1165\/rcmb.2009-0206TR","volume":"42","author":"NH Heintz","year":"2010","unstructured":"Heintz NH, Janssen-Heininger YM, Mossman BT: Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 2010, 42: 133-139. 10.1165\/rcmb.2009-0206TR","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1270_CR16","first-page":"4239","volume":"27","author":"DM Jablons","year":"2007","unstructured":"Jablons DM, Eguchi K: Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth. Anticancer Res. 2007, 27: 4239-4242.","journal-title":"Anticancer Res"},{"key":"1270_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/JTO.0b013e31820cdd6f","volume":"6","author":"D Stoppoloni","year":"2011","unstructured":"Stoppoloni D, Salvatori L, Biroccio A, D\u2019Angelo C, Muti P, Verdina A, Sacchi A, Vincenzi B, Baldi A, Galati R: Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells. J Thorac Oncol. 2011, 6: 583-591. 10.1097\/JTO.0b013e31820cdd6f","journal-title":"J Thorac Oncol"},{"key":"1270_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-12-1","volume":"12","author":"B Nuvoli","year":"2013","unstructured":"Nuvoli B, Galati R: Cyclooxygenase-2, epidermal growth factor receptor and aromatase signalling in inflammation and mesothelioma. Mol Cancer Ther. 2013, 12: 1-9. 10.1186\/1476-4598-12-1.","journal-title":"Mol Cancer Ther"},{"key":"1270_CR19","volume-title":"World Health Organization international histological classification of tumors","author":"WD Travis","year":"1999","unstructured":"Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E: Histological typing of lung and pleural tumors. World Health Organization international histological classification of tumors. Edited by: Springer-Verlag. 1999, Berlin: Springer-Verlag, 3","edition":"3"},{"key":"1270_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/000313481007600418","volume":"76","author":"EC Tudor","year":"2010","unstructured":"Tudor EC, Chua TC, Liauw W, Morris DL: Risk factors and clinicopathological study of prognostic factors in th\u00e8 peritoneal mesothelioma. Am Surg. 2010, 76: 400-405.","journal-title":"Am Surg"},{"key":"1270_CR21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00432-013-1408-2","volume":"139","author":"K Pillai","year":"2013","unstructured":"Pillai K, Pourgholami MH, Chua TC, Morris DL: Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 2013, 139: 987-994. 10.1007\/s00432-013-1408-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"1270_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/modpathol.3800067","volume":"17","author":"JK Trupiano","year":"2004","unstructured":"Trupiano JK, Geisinger KR, Willingham MC, Manders P, Zbieranski N, Case D, Levine EA: Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol. 2004, 17: 476-481. 10.1038\/modpathol.3800067","journal-title":"Mod Pathol"},{"key":"1270_CR23","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1158\/0008-5472.CAN-08-4523","volume":"69","author":"G Pinton","year":"2009","unstructured":"Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L: Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009, 69: 4598-4604. 10.1158\/0008-5472.CAN-08-4523","journal-title":"Cancer Res"},{"key":"1270_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1476-4598-8-109","volume":"8","author":"A Koutras","year":"2009","unstructured":"Koutras A, Giannopoulou E, Kritikou I, Antonacopoulou A, Evans TR, Papavassiliou AG, Kalofonos H: Antiproliferative effect of exemestane in lung cancer cells. Mol Cancer. 2009, 8: 109- 10.1186\/1476-4598-8-109","journal-title":"Mol Cancer"},{"key":"1270_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1476-4598-6-81","volume":"6","author":"ME Ramos-Nino","year":"2007","unstructured":"Ramos-Nino ME, Blumen SR, Pass H, Mossman BT: Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas. Mol Cancer. 2007, 6: 81- 10.1186\/1476-4598-6-81","journal-title":"Mol Cancer"},{"key":"1270_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1677\/erc.0.0060187","volume":"6","author":"WR Miller","year":"1999","unstructured":"Miller WR: Biology of aromatase inhibitors: pharmacology\/endocrinology within the breast. Endocr Relat Cancer. 1999, 6: 187-195. 10.1677\/erc.0.0060187","journal-title":"Endocr Relat Cancer"},{"key":"1270_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1023\/A:1016121822916","volume":"74","author":"RW Brueggemeier","year":"2002","unstructured":"Brueggemeier RW: Overview of the pharmacology of the aromatase inactivator exemestane. Breast Cancer Res Treat. 2002, 74: 177-185. 10.1023\/A:1016121822916","journal-title":"Breast Cancer Res Treat"},{"key":"1270_CR28","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/cncr.10908","volume":"95","author":"AU Buzdar","year":"2002","unstructured":"Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM: An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002, 95: 2006-2016. 10.1002\/cncr.10908","journal-title":"Cancer"},{"key":"1270_CR29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2165\/00003495-200969070-00007","volume":"69","author":"ED Deeks","year":"2009","unstructured":"Deeks ED, Scott LJ: Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs. 2009, 69: 889-918. 10.2165\/00003495-200969070-00007","journal-title":"Drugs"},{"key":"1270_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0960-0760(01)00132-7","volume":"79","author":"S Chen","year":"2001","unstructured":"Chen S, Zhou D, Yang C, Okubo T, Kinoshita Y, Yu B, Kao YC, Itoh T: Modulation of aromatase expression in human breast tissue. J Steroid Biochem Mol Biol. 2001, 79: 35-40. 10.1016\/S0960-0760(01)00132-7","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1270_CR31","first-page":"4852","volume":"8","author":"M Hagiwara","year":"1993","unstructured":"Hagiwara M, Brindle P, Harootunian A, Armstrong R, Rivier J, Vale W, Tsien R, Montminy MR: Coupling of hormonal stimulation and transcription via the cyclic AMP-responsive factor CREB is rate limited by nuclear entry of protein kinase A. Mol Cell Biol. 1993, 8: 4852-4859.","journal-title":"Mol Cell Biol"},{"key":"1270_CR32","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1146\/annurev.bi.59.070190.004543","volume":"59","author":"SS Taylor","year":"1990","unstructured":"Taylor SS, Buechler JA, Yonemoto W: cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem. 1990, 59: 971-1005. 10.1146\/annurev.bi.59.070190.004543","journal-title":"Annu Rev Biochem"},{"key":"1270_CR33","doi-asserted-by":"publisher","first-page":"13443","DOI":"10.1074\/jbc.M109869200","volume":"277","author":"R Kopperud","year":"2002","unstructured":"Kopperud R, Christensen AE, Kjarland E, Viste K, Kleivdal H, D\u00f8skeland SO: Formation of inactive cAMP-saturated holoenzyme of cAMP-dependent protein kinase under physiological conditions. J Biol Chem. 2002, 277: 13443-13448. 10.1074\/jbc.M109869200","journal-title":"J Biol Chem"},{"key":"1270_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0079-6107(98)00059-5","volume":"71","author":"CM Smith","year":"1999","unstructured":"Smith CM, Radzio-Andzelm E, Madhusudan Akamine P, Taylor SS: The catalytic subunit of cAMP-dependent protein kinase: prototype for an extended network of communication. Prog Biophys Mol Biol. 1999, 71: 313-341. 10.1016\/S0079-6107(98)00059-5","journal-title":"Prog Biophys Mol Biol"},{"key":"1270_CR35","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1091\/mbc.4.10.993","volume":"4","author":"AT Harootunian","year":"1993","unstructured":"Harootunian AT, Adams SR, Wen W, Meinkoth JL, Taylor SS, Tsien RY: Movement of the free catalytic subunit of cAMP-dependent protein kinase into and out of the nucleus can be explained by diffusion. Mol Biol Cell. 1993, 4: 993-1002. 10.1091\/mbc.4.10.993","journal-title":"Mol Biol Cell"},{"key":"1270_CR36","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s13277-012-0473-5","volume":"33","author":"T Hanagiri","year":"2012","unstructured":"Hanagiri T, Shinohara S, Takenaka M, Shigematsu Y, Yasuda M, Shimokawa H, Nagata Y, Nakagawa M, Uramoto H, So T, Tanaka F: Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma. Tumour Biol. 2012, 33: 2135-2141. 10.1007\/s13277-012-0473-5","journal-title":"Tumour Biol"},{"key":"1270_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/mp.51.4.191","volume":"51","author":"RJ Sneath","year":"1998","unstructured":"Sneath RJ, Mangham DC: The normal structure and function of CD44 and its role in neoplasia. Mol Pathol. 1998, 51: 191-200. 10.1136\/mp.51.4.191","journal-title":"Mol Pathol"},{"key":"1270_CR38","first-page":"5275","volume":"61","author":"RC Bates","year":"2001","unstructured":"Bates RC, Edwards NS, Burns GF, Fisher DE: A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase\/Akt in colon carcinoma cells. Cancer Res. 2001, 61: 5275-5283.","journal-title":"Cancer Res"},{"key":"1270_CR39","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1210\/endo.138.9.5489","volume":"138","author":"J Waiters","year":"1997","unstructured":"Waiters J, Campbell JS, Cunningham MJ, Krebs EG, Dorsa DM: Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology. 1997, 138: 4030-4033. 10.1210\/endo.138.9.5489","journal-title":"Endocrinology"},{"key":"1270_CR40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1161\/01.ATV.0000053846.71621.93","volume":"23","author":"T Simoncini","year":"2003","unstructured":"Simoncini T, Rabkin E, Liao JK: Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol. 2003, 23: 198-203. 10.1161\/01.ATV.0000053846.71621.93","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1270_CR41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S1043-2760(99)00190-3","volume":"10","author":"MJ Kelly","year":"1999","unstructured":"Kelly MJ, Wagner EJ: Estrogen modulation of G-protein-coupled receptors. Trends Endocrinol Metab. 1999, 10: 369-374. 10.1016\/S1043-2760(99)00190-3","journal-title":"Trends Endocrinol Metab"},{"key":"1270_CR42","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1210\/mend.16.1.0758","volume":"16","author":"EJ Filardo","year":"2002","unstructured":"Filardo EJ, Quinn JA, Frackelton AR, Bland KI: Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 2002, 16: 70-84. 10.1210\/mend.16.1.0758","journal-title":"Mol Endocrinol"},{"key":"1270_CR43","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1158\/1078-0432.CCR-06-1056","volume":"12","author":"EP Spugnini","year":"2006","unstructured":"Spugnini EP, Cardillo I, Verdina A, Crispi S, Saviozzi S, Calogero R, Nebbioso A, Altucci L, Cortese G, Galati R, Chien J, Shridhar V, Vincenzi B, Citro G, Cognetti F, Sacchi A, Baldi A: Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res. 2006, 12: 6133-6143. 10.1158\/1078-0432.CCR-06-1056","journal-title":"Clin Cancer Res"},{"key":"1270_CR44","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1038\/onc.2011.485","volume":"31","author":"C Canino","year":"2012","unstructured":"Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, Borsellino G, Galati R, Battistini L, Blandino R, Facciolo F, Citro G, Strano S, Muti P, Blandino G, Cioce M: SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogen. 2012, 31: 3148-3163. 10.1038\/onc.2011.485.","journal-title":"Oncogen"},{"key":"1270_CR45","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/1078-0432.982.11.3","volume":"11","author":"M Hazarika","year":"2005","unstructured":"Hazarika M, White RM, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R: Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res. 2005, 11: 982-992.","journal-title":"Clin Cancer Res"},{"key":"1270_CR46","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","volume":"9","author":"M Hazarika","year":"2004","unstructured":"Hazarika M, White RM, Johnson JR, Pazdur R: FDA drug approval summaries: pemetrexed (Alimta). Oncologist. 2004, 9: 482-488. 10.1634\/theoncologist.9-5-482","journal-title":"Oncologist"},{"key":"1270_CR47","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1021\/jm300262w","volume":"55","author":"C Varela","year":"2012","unstructured":"Varela C, Tavares da Silva EJ, Amaral C, Correia da Silva G, Baptista T, Alcaro S, Costa G, Carvalho RA, Teixeira NA, Roleira FM: New structure-activity relationships of A- and D-ring modified steroidal aromatase inhibitors: design, synthesis, and biochemical evaluation. J Med Chem. 2012, 55: 3992-4002. 10.1021\/jm300262w","journal-title":"J Med Chem"},{"key":"1270_CR48","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","volume":"26","author":"RJ Paridaens","year":"2008","unstructured":"Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European organisation for research and treatment of cancer breast cancer cooperative group. J Clin Oncol. 2008, 26: 4883-4890. 10.1200\/JCO.2007.14.4659","journal-title":"J Clin Oncol"},{"key":"1270_CR49","doi-asserted-by":"publisher","first-page":"19065","DOI":"10.1073\/pnas.1318247110","volume":"110","author":"H Liu","year":"2013","unstructured":"Liu H, Talalay P: Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention. Proc Natl Acad Sci USA. 2013, 110: 19065-19070. 10.1073\/pnas.1318247110","journal-title":"Proc Natl Acad Sci USA"},{"key":"1270_CR50","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/cncr.23904","volume":"113","author":"D Stoppoloni","year":"2008","unstructured":"Stoppoloni D, Cardillo I, Verdina A, Vincenzi B, Menegozzo S, Santini M, Sacchi A, Baldi A, Galati R: Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis. Cancer. 2008, 113: 2761-2769. 10.1002\/cncr.23904","journal-title":"Cancer"},{"key":"1270_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1476-4598-9-27","volume":"9","author":"D Stoppoloni","year":"2010","unstructured":"Stoppoloni D, Canino C, Cardillo I, Verdina A, Baldi A, Sacchi A, Galati R: Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer. 2010, 9: 27- 10.1186\/1476-4598-9-27","journal-title":"Mol Cancer"}],"updated-by":[{"DOI":"10.1186\/s12943-022-01692-9","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"record-id":"41217"},{"DOI":"10.1186\/s12943-022-01692-9","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000}}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-13-69.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T14:06:39Z","timestamp":1671458799000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-13-69"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12]]}},"alternative-id":["1270"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-13-69","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,21]]},"assertion":[{"value":"2 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12943-022-01692-9","URL":"https:\/\/doi.org\/10.1186\/s12943-022-01692-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"69"}}